Saturday, October 3, 2026

USD/EUR Bearish By 3% In The Last 21 Sessions

USD/EUR Bearish By 3% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 3.75% for the last 21 sessions. At 20:09 EST on Wednesday, 12 April, USD/EUR (USDEUR) is $0.91.

USD/EUR's yearly highs and lows, it's 0.287% up from its 52-week low and 13.232% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy to drop toward 128 by end-June – ING. According to FXStreet on Tuesday, 11 April, "Economists at ING expect steady outperformance of the Yen through the year and forecast USD/JPY at 128 by the end of June."
  • Usd/jpy skids below 133.50, upside looks favored as boj supports expansionary policy. According to FXStreet on Tuesday, 11 April, "The USD/JPY pair has corrected below the critical support of 133.50 in the Asian session after a stellar upside move to near 133.87. ", "It is worth noting that the proportion of correction in the USD/JPY pair is much less than the corrective move in the USD Index, which indicates weakness in the Japanese Yen. "
  • According to FXStreet on Tuesday, 11 April, "Meanwhile, USD/JPY is feeling the pull of gravity, as it drops below 133.50, down 0.16% on the day."
  • Usd/jpy price analysis: bulls take a breather on their way to 134.50. According to FXStreet on Wednesday, 12 April, "On the flip side, a daily closing below the previously stated DMA confluence, near 133.35-25, could quickly drag the USD/JPY prices towards a three-month-long ascending support line, close to 131.10 at the latest.", "Following that, the 200-DMA hurdle of around 137.20 acts as the last defense of the USD/JPY bears."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com